Save Bijlee, Big B appeals to animal lovers

Last Updated: Tuesday, June 18, 2013, 13:07

What is Amitabh Bachchan concerned about? The ailing elephant Bijlee.

Wockhardt Q4 net profit at Rs 334.76 crore

Last Updated: Monday, May 27, 2013, 17:18

It had posted a net loss of Rs 191.64 crore for the corresponding period previous fiscal, the company said in a filing to BSE.

Wockhardt shares fall for 2nd day; slump 19%

Last Updated: Friday, May 24, 2013, 12:04

Similarly at the NSE, the stock nosedived by 19.31 percent to Rs 1,060.

Wockhardt shares plummet 20%; stock hits lower circuit

Last Updated: Thursday, May 23, 2013, 23:29

Wockhardt's scrip tumbled by 20 percent to Rs 1,315.25 -- its lowest trading permissible limit for the day on the BSE.

USFDA import alert could impact co's biz by $100 mn: Wockhardt

Last Updated: Thursday, May 23, 2013, 19:50

"USFDA has put an import alert on one of our facilities, at Waluj, near Aurangabad. We estimate that it would impact our business by USD 100 million on an annualised basis," Wockhardt Chairman Habil Khorakiwala said.

MSCI India adds Wockhardt, OIL, GSK Consumer, Apollo Hospitals

Last Updated: Thursday, May 16, 2013, 13:42

Apollo Hospitals, Oil India, Wockhardt and GlaxoSmithKline Consumer Healthcare have been added to the MSCI (Morgan Stanley Capital International) India index.

Wockhardt Q3 net zooms two-fold to Rs 428 crore

Last Updated: Thursday, February 14, 2013, 18:00

Drug firm Wockhardt on Thursday reported over two-fold increase in consolidated net profit at Rs 428 crore for the third quarter ended December 31, 2012, on robust sales across international markets, including US.

Wockhardt gets USFDA nod to market anti-epilepsy tablets

Last Updated: Tuesday, January 8, 2013, 15:34

Drug firm Wockhardt on Tuesday said it has received final approval from the US health regulator to market generic Lamotrigine tablets - used for treatment of epilepsy - in America.

US, Europe to be focus markets for future growth: Wockhardt

Last Updated: Tuesday, December 4, 2012, 13:11

Drug maker Wockhardt Tuesday said it expects the US and European markets to continue to be its mainstay in the coming years while it seeks to enhance R&D capabilities and focus on introducing new advanced therapies.